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Purpose of the study
Early clinical experience with DRV/r plus ETR in several
small pharmacokinetic and efficacy studies, as well as the
ongoing DUET trials, demonstrated antiretroviral (ARV)
activity and tolerability in treatment-experienced patients
(pts). ENF has shown activity in treatment-experienced
pts but requires twice daily subcutaneous injections, com-
monly leading to dosing fatigue and injection site reac-
tions. This ongoing 48-week pilot study evaluates the
efficacy and tolerability of the combination of DRV/r and
ETR when substituted for ENF and current PI (and NNRTI,
if applicable) in a virologically suppressive regimen. We
report efficacy, safety and tolerability of the DRV/r and
ETR-containing regimen at week 24.
Methods
Eligible HIV-infected adults were on a PI-based regimen
including ENF, had viral load (VL) ≤400 copies/mL for at
least 6 months, and had a history of 3-class drug resistance
or ARV failure. Pts declined to continue ENF or had phy-
sicians' recommendation to discontinue. At study entry,
all pts discontinued ENF, PI(s) and NNRTI(s), if applica-
ble (NRTIs were continued) and substituted DRV/r 600/
100 mg BID plus ETR 200 mg BID. Primary end-point:
proportion of pts maintaining VL ≤400 copies/mL at 24
and 48 weeks. Virologic response, CD4 count, and lab val-
ues are reported as missing equals failure, last observation
carried forward, and observed, respectively.
Summary of results
Target enrollment (40 pts) was not reached due to short-
age of eligible pts. Ten male pts enrolled: median age 48
yrs; six Caucasian and four Hispanic; all baseline (BL) VL
<50 copies/mL; median BL CD4 301 cells/mm3. One pt
discontinued due to dizziness (doubtfully-related) at
week 8. All nine pts completing week 24 maintained VL
<50 copies/mL. Median increase in CD4 count was 17
cells/mm3. Most common treatment-related AEs were
fatigue (n = 4), rash (n = 3), headache (n = 3) and diarrhea
(n = 3). One serious AE (cholecystitis; doubtfully-related)
and two grade 3/4 AEs (nausea and weight loss; not
related) were reported. Median changes (min;max) in mg/
dL from baseline to week 24 for triglycerides, total choles-
terol (TC), HDL, LDL and TC/HDL ratio were -13(-
228;118), -15(-31;60), -2(-15;17), -7(-27;6) and 0(-
1.16;1.20), respectively.
Conclusion
In this study, following substitution of DRV/r and ETR for
ENF, PI(s) and NNRTI(s), 9/9 previously suppressed pts
who completed week 24 maintained VL <50 copies/mL.
DRV/r and ETR were generally safe and well tolerated.
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